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Background: This population-based study aimed to examine the incidence, patterns and results of
multimodal management of metastatic colorectal cancer.
Methods: A retrospective population-based study was conducted on patients with metastatic colorec-
tal cancer in Central Finland in 2000–2015. Clinical and histopathological data were retrieved and
descriptive analysis was conducted to determine the pattern of metastatic disease, defined as syn-
chronous, early metachronous (within 12months of diagnosis of primary disease) and late metachronous
(more than 12months after diagnosis). Subgroups were compared for resection and overall survival
(OS) rates.
Results: Of 1671 patients, 296 (17⋅7 per cent) had synchronous metastases, and 255 (19⋅6 per cent)
of 1302 patients with resected stage I–III tumours developed metachronous metastases (94 early and
161 late metastases). Liver, pulmonary and intraperitoneal metastases were the most common sites.
The commonest metastatic patterns were a combination of liver and lung metastases. The overall
metastasectomy rate for patients with synchronous metastases was 16⋅2 per cent; in this subgroup, 3-
and 5-year OS rates after any resection were 63 and 44 per cent respectively, compared with 7⋅1 and
3⋅3 per cent following no resection (P< 0⋅001). The resection rate was higher for late than for early
metachronous disease (28⋅0 versus 17 per cent respectively; P= 0⋅048). Three- and 5-year OS rates after
any resection of metachronous metastases were 78 and 62 per cent respectively versus 42⋅1 and 18⋅2 per
cent with no metastasectomy (P<0⋅001). Similarly, 3- and 5-year OS rates after any metastasectomy for
early metachronous metastases were 57 and 50 per cent versus 84 and 66 per cent for late metachronous
metastases (P=0⋅293).
Conclusion: The proportion of patients with metastatic colorectal cancer was consistent with that in
earlier population-based studies, as were resection rates for liver and lung metastases and survival after
resection. Differentiation between synchronous, early and late metachronous metastases can improve
assessment of resectability and survival.
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Introduction
Colorectal carcinoma is the third most common cancer
worldwide1,2 and the fourth leading cause of cancer death1.
Over the years, many improvements have been made
in the management of primary and metastatic colorectal
cancer3–5. These include diagnostic procedures, extended
indications for resection of metastatic disease, improve-
ment in perioperative care, and the development of effec-
tive neoadjuvant, adjuvant and palliative treatments. The
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impact of these improvements at a population level is not
well known6.
Only a few population-based studies7–9 have been pub-
lished assessing the incidence and patterns of metastatic
colorectal cancer and survival. According to these stud-
ies, 15–30 per cent of patients with colorectal cancer have
synchronous or metachronous metastases. The observed
rate of synchronous liver metastasis ranges from 14⋅5 to 19
per cent7,10–13, and that of metachronous liver metastases
ranges from 8⋅1 to 12⋅8 per cent8,10,11,13.
The aim of this study was to examine the incidence and
patterns of metastatic disease, surgical management and
survival in patients with metastatic colorectal cancer by
reviewing all diagnosed colorectal cancers from 2000 to
2015 in a well defined population in Central Finland.
Methods
According to Finnish healthcare policy, all municipalities
are responsible for arranging specialized hospital care for
their residents. Each hospital district organizes and pro-
vides specialized hospital care for the population in its area.
The Central Hospital of Central Finland is the only gas-
troenterological surgery unit in the Central Finland hospi-
tal district. The annual population of the area was obtained
from Statistics Finland, and averaged around 270 000 dur-
ing the study period, from 1 January 2000 to 31 December
2015. All patients with primary and metastatic colorectal
cancer are managed in this hospital, with no referrals to
other hospitals.
Patients diagnosed with primary colorectal cancer during
the study interval were identified using the histopathologi-
cal registry of the hospital, which covers all colorectal can-
cers diagnosed in the area. Clinical and histopathological
data, as well as recurrence data, were retrieved retrospec-
tively from hospital records. Colonoscopy, thoracoabdom-
inal CT, endorectal ultrasonography and pelvic MRI were
used to diagnose and stage primary colorectal tumours.
All patients with colorectal primary and metastatic disease
were discussed in multidisciplinary team (MDT) meetings
before definitive treatment decisions were made.
Surgery for primary colorectal cancers was performed
according to international guidelines3, mostly with a
laparoscopic approach, complete mesocolic and total
mesorectal excision principles. Liver surgery was per-
formed according to international guidelines4,5, using
intraoperative ultrasound imaging, a cavitron ultrasonic
surgical aspirator and bipolar energy devices. After 2011,
lung metastases were treated primarily with a thoraco-
scopic approach using wedge resection or segmentectomy.
Tumours were staged by staff pathologists according to
the UICC/TNM classification14.
Neoadjuvant and adjuvant treatments for primary
and metastatic disease were administered according to
international guidelines3. Since 2005, adjuvant post-
operative chemotherapy for 6months, consisting of
5-fluorouracil (5-FU) and oral folic acid, oral capecitabine
or folic acid, 5-FU and oxaliplatin (FOLFOX regimen),
was prescribed to medically fit patients with stage III
tumours or high-risk stage II disease. Patients with
liver metastases received perioperative chemotherapy
with the FOLFOX regimen, with or without bio-
logicals, according to the decision taken at the MDT
meeting.
Surgery for advanced disease was performed when
appropriate, according to the local MDT. Significant
co-morbidity and inadequate physical and mental per-
formance status were contraindications for surgery.
Unresectable metastatic disease was defined as the inability
to achieve complete resection of all metastases, liver and
lungmetastases combined with more than one extrahepatic
site, extensive extrahepatic metastatic disease, inability to
leave at least 30–40 per cent of functional liver volume in
the case of liver metastases, and progression of metastatic
disease during chemotherapy.
The study was approved by the hospital administrative
and ethics board (Dnro13U/2011 and 1/2016) and the
National Authority forWelfare andHealth (Valvira) (Dnro
3916/06.01.03.01/2016).
Data collection
The study variables for primary tumours included age,
sex, tumour location, TNM/UICC stage, and date of
surgery. The date of diagnosis of metastatic disease,
metastatic site, and number and size of the metastases were
recorded. According to an international consensus meeting
report5, synchronousmetastases were defined asmetastases
detected before or at the time of diagnosis of the primary
cancer. Early metachronous metastases were defined as
metastases detected at or within 12months of diagnosis
of the primary tumour, and late metachronous metastases
as those detected more than 12months after diagnosis of
the primary5.
Outcome measures
Outcome measures included resection rate, defined as
number of metastasectomies with curative intent, and over-
all survival (OS), defined as the percentage of patients alive
at 3 and 5 years after the date of diagnosis of metastases or
the start of therapy.
Follow-up after surgery for primary tumours and metas-
tases included carcinoembryonic antigen estimation,
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clinical examination, ultrasound investigation of the liver,
and chest radiography every 6months during the first
3 years, and annually thereafter up to October 2017. Fur-
ther characterization of recurrent metastases was done by
CT and/or MRI, and after 2005 also by CT–PET. Locally
recurrent disease in the bowel was assessed by CT/pelvic
MRI and endoscopy. Locoregional recurrence was defined
as a recurrent tumour at the anastomotic site or locore-
gionally in the abdomen, and diagnosed by CT, MRI and
endoscopy to ascertain whether newly diagnosed distant
metastasis was absent or present. Causes of death were
obtained from hospital records and the National Cause of
Death Registry.
Statistical analysis
Results are given as mean(s.d.) or median (i.q.r.) values.
Pearson’s χ2 or Fisher’s exact tests were used to com-
pare frequencies, and Student’s t test, Mann–Whitney U
test and Kruskal–Wallis test for continuous variables. The
Kaplan–Meier method was used to calculate survival, and
differences between groups were compared with the log
rank test. Survival times were calculated from the date
of primary surgery to the date of death or the end of
follow-up. As the number of patients with rectal can-
cer and a complete pathological response after chemora-
diotherapy was small, these patients were included with
patients with stage I disease for purposes of statistical cal-
culation. All statistical tests were two-sided. P< 0⋅050 was
considered significant. STATA® release 11 2009 (Stata-
Corp, College Station, Texas, USA) was used for statistical
analysis.
Results
A total of 1671 patients met the criteria of having been
diagnosed and treated for colorectal cancer at Cen-
tral Finland Hospital District during the study period.
Baseline characteristics of the patients are shown in
Table 1. Patients with metastatic disease were younger than
those without metastases (mean 68⋅8 versus 71⋅1 years
respectively; P< 0⋅001), with no significant differ-
ences in sex and primary tumour site distribution. Of
the 1671 primary tumours 1471 (88⋅0 per cent) were
resected. Primary tumours were resected less often
in patients with metastatic colorectal cancer than in
those without metastases (77⋅0 versus 93⋅5 per cent;
P< 0⋅001).
Some 200 patients (12⋅0 per cent) did not have surgery for
the primary tumour, because of significant co-morbidity,
old age, locally unresectable primary cancer, unresectabil-
ity of metastases or patient preference. Rectal carcinomas
were unresectable more frequently than colonic carci-
nomas (15⋅6 versus 9⋅9 per cent respectively; P= 0⋅001).
The median number of lymph nodes investigated was
12 (i.q.r. 6–17) in those who had primary tumour resec-
tion. Of patients with metastatic colorectal cancer, 51⋅0
per cent had regional lymph node metastases compared
with 25⋅8 per cent of patients without metastatic disease
(Table 1).
Characteristics of patients with synchronous versus
metachronous metastases
Metastatic disease was diagnosed in 551 (33⋅0 per cent)
of the 1671 patients, of which 296 (17⋅7 per cent) were
synchronous metastases (Table 2). Of 1302 resected stage
I–III tumours, 255 (19⋅6 per cent) were metachronous,
94 (7⋅2 per cent) early metachronous, and 161 (12⋅4 per
cent) late metachronous metastases. Tumour site distri-
bution (colon versus rectum, or right versus left colon)
did not influence the incidence or distribution of syn-
chronous and metachronous liver, pulmonary or intraperi-
toneal metastases. The node positivity rate for primary
colorectal cancers was highest in the early metachronous
group (68⋅1 per cent) compared with the latemetachronous
(53⋅4 per cent) or synchronous (44⋅3 per cent) group
(P< 0⋅001).
Overall, metastatic sites and patterns, as well as the
number and size of liver metastases, varied significantly
between synchronous, early and late metachronous metas-
tases (Table 2).
Metastatic patterns varied significantly between the study
groups. The most common metastatic patterns were com-
binations of liver and lung metastases, followed by com-
bined liver and extrahepatic (no lung) metastases, and
combined liver, lung and extrahepatic metastases (Table 2).
The proportion of patients having only intra-abdominal,
extrahepatic recurrences was highest in the early and late
metachronous groups.
Management and survival of patients
with synchronous metastases
The primary tumour was resected in 169 (57⋅1 per cent) of
the 296 patients with synchronous metastases. The over-
all metastasectomy rate was 16⋅2 per cent (48 of 296),
and included liver resection in 36 patients (with combined
radiofrequency ablation in 5), liver and lung resection in
eight, and lung resections in four patients. Liver resection
was performed in 44 (18⋅3 per cent) of the 240 patients
with synchronous liver metastases, and lung resection in
12 (13 per cent) of the 89 patients with lung metastases. Of
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Table 1 Characteristics of patients with and without distant metastases
All patients
(n=1671)
No metastases
(n=1120)
Synchronous and
metachronous metastases
(n=551) P†
Age (years)* 70⋅3(11⋅3) 71⋅1(11⋅2) 68⋅8(11⋅5) <0⋅001‡
Age group (years) 0⋅005
<65 497 (29⋅7) 305 (27⋅2) 192 (34⋅8)
65–75 575 (34⋅4) 395 (35⋅3) 180 (32⋅7)
>75 599 (35⋅8) 420 (37⋅5) 179 (32⋅5)
Male sex 904 (54⋅1) 606 (54⋅1) 298 (54⋅1) 0⋅993
Primary tumour site 0⋅871
Colon 1069 (64⋅0) 718 (64⋅1) 351 (63⋅7)
Rectum 602 (36⋅0) 402 (35⋅9) 200 (36⋅3)
Side of colon 0⋅472
Right 623 (58⋅3) 413 (57⋅5) 210 (59⋅8)
Left 446 (41⋅7) 305 (42⋅5) 141 (40⋅2)
pT category <0⋅001
pCR (complete response) 8 (0⋅5) 8 (0⋅7) 0 (0)
pT1 147 (8⋅8) 134 (12⋅0) 13 (2⋅4)
pT2 258 (15⋅4) 223 (19⋅9) 35 (6⋅4)
pT3 832 (49⋅8) 584 (52⋅1) 248 (45⋅0)
pT4 226 (13⋅5) 98 (8⋅8) 128 (23⋅2)
Missing 200 (12⋅0) 73 (6⋅6) 127 (23⋅0)
pN category <0⋅001
pN0 900 (53⋅9) 758 (67⋅7) 142 (25⋅8)
pN1 342 (20⋅5) 202 (18⋅0) 140 (25⋅4)
pN2 228 (13⋅6) 87 (7⋅8) 141 (25⋅6)
Missing 201 (12⋅0) 73 (6⋅5) 128 (23⋅2)
M category <0⋅001
M0 1303 (78⋅0) 1048 (93⋅6) 255 (46⋅3)
M1 296 (17⋅7) 0 (0) 296 (53⋅7)
Missing 72 (4⋅3) 72 (6⋅4) 0 (0)
UICC tumour stage <0⋅001
pCR (complete response) 8 (0⋅5) 8 (0⋅7) 0 (0)
I 342 (20⋅5) 308 (27⋅5) 34 (6⋅2)
II 513 (30⋅7) 442 (39⋅5) 71 (12⋅9)
III 439 (26⋅3) 289 (25⋅8) 150 (27⋅2)
IV 296 (17⋅7) 0 (0) 296 (53⋅7)
Missing 73 (4⋅4) 73 (6⋅5) 0 (0)
Resection of primary tumour <0⋅001
Yes 1471 (88⋅0) 1047 (93⋅5) 424 (77⋅0)
No 200 (12⋅0) 73 (6⋅5) 127 (23⋅0)
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). †χ2 or Fisher’s exact test, except ‡Student’s t test.
the 44 patients with synchronous liver metastases undergo-
ing liver resection, neoadjuvant chemotherapy was given
to 31 (70 per cent) and adjuvant chemotherapy to 39
(89 per cent).
The 3- and 5-year OS rates after any resection of syn-
chronous metastases were 63 and 44 per cent respectively
compared with 7⋅1 and 3⋅3 per cent in patients who did
not have resection (P< 0⋅001) (Fig. 1). Three- and 5-year
OS rates after liver resection were 64 and 44 per cent
respectively versus 4⋅4 and 0⋅8 per cent with no liver resec-
tion (P< 0⋅001).
Management and survival of patients
with metachronous metastases
Metachronous metastases were detected in 255 (19⋅6 per
cent) of the 1302 patients with stage I–III tumours who
had bowel resection for primary colorectal cancer: early
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Table 2 Characteristics of 551 patients with synchronous and metachronous metastases
Synchronous
(n=296)
Early metachronous
(n=94)
Late metachronous
(n=161) P†
Age (years)* 68⋅7(11⋅6) 70⋅6(12⋅0) 67⋅8(11⋅0) 0⋅171‡
Age group 0⋅076
<65 107 (36⋅1) 28 (30) 57 (35⋅4)
65–75 92 (31⋅1) 26 (28) 62 (38⋅5)
>75 97 (32⋅8) 40 (43) 42 (26⋅1)
Male sex 158 (53⋅4) 52 (55) 88 (54⋅7) 0⋅933
Primary tumour site 0⋅532
Colon 194 (65⋅5) 60 (64) 97 (60⋅2)
Rectum 102 (34⋅5) 34 (36) 64 (39⋅8)
Side of colon 0⋅488
Right 114 (58⋅8) 40 (67) 56 (58)
Left 80 (41⋅2) 20 (33) 41 (42)
UICC tumour stage <0⋅001
I 0 (0) 8 (9) 26 (16⋅1) 0⋅054§
II 0 (0) 22 (23) 49 (30⋅4)
III 0 (0) 64 (68) 86 (53⋅4)
IV 296 (100) 0 (0) 0 (0)
Most common metastatic site at presentation
Liver 240 (81⋅1) 51 (54) 83 (51⋅6) <0⋅001
Lung 89 (30⋅1) 29 (31) 66 (41⋅0) 0⋅052
Intra-abdominal, extrahepatic 76 (25⋅7) 54 (57) 63 (39⋅1) <0⋅001
Bone 3 (1⋅0) 4 (4) 5 (3⋅1) 0⋅109
Brain 5 (1⋅7) 4 (4) 5 (3⋅1) 0⋅335
Size of largest liver metastasis (cm) 0⋅015
<5 157 (65⋅4) 37 (73) 65 (78)
≥5 78 (32⋅5) 10 (20) 17 (20)
Missing 5 (2⋅1) 4 (8) 1 (1)
No. of liver metastases <0⋅001
1 40 (16⋅7) 16 (31) 37 (45)
2–3 62 (25⋅8) 15 (29) 30 (36)
>4 133 (55⋅4) 16 (31) 15 (18)
Missing 5 (2⋅1) 4 (8) 1 (1)
Pattern of distant metastasis at diagnosis <0⋅001
Liver only 148 (50⋅0) 25 (27) 52 (32⋅3)
Lung only 20 (6⋅8) 7 (7) 34 (21⋅1)
Liver and lung 52 (17⋅6) 8 (9) 12 (7⋅5)
Liver and extrahepatic (no lung) 30 (10⋅1) 13 (14) 13 (8⋅1)
Lung and extrahepatic (no liver) 7 (2⋅4) 9 (10) 14 (8⋅7)
Liver, lung and extrahepatic 10 (3⋅4) 5 (5) 6 (3⋅7)
Extrahepatic only 29 (9⋅8) 27 (29) 30 (18⋅6)
Resection of primary tumour 169 (57⋅1) 94 (100) 161 (100) <0⋅001
Metastasectomy 0⋅007
No 248 (83⋅8) 78 (83) 116 (72⋅0) 0⋅048§
Yes 48 (16⋅2) 16 (17) 45 (28⋅0)
Liver resection 44 of 240 (18⋅3) 15 of 51 (29) 31 of 83 (37) 0⋅003
Lung resection 12 of 89 (13) 6 of 29 (21) 17 of 66 (26) 0⋅025
Extrahepatic, intra-abdominal resection 1 of 76 (1) 2 of 54 (4) 1 of 63 (2) 0⋅392
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). †χ2 or Fisher’s exact test, except ‡Student’s t test (synchronous
versus metachronous metastases) and §χ2 or Fisher’s exact test (early versus late metachronous metastases).
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Fig. 1 Kaplan–Meier analysis of overall survival in 296 patients
with synchronous metastases who had resection of the pri-
mary colorectal tumour with or without metastasectomy
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metachronous 94 (7⋅2 per cent) and late metachronous
161 (12⋅4 per cent) metastases (Table 2). Of these 255
patients, 61 (23⋅9 per cent) underwent metastasectomy.
Liver resection was performed in 46 (34⋅3 per cent) of
the 134 patients with liver metastases, and lung resection
in 23 (24 per cent) of the 95 patients with lung metas-
tases: liver only resection in 38 patients (28 per cent) and
both liver and lung resection in eight (6 per cent). Of the
46 patients with metachronous liver metastases undergo-
ing liver resection, neoadjuvant chemotherapy was given
to 21 patients (46 per cent) and adjuvant chemotherapy to
41 (89 per cent). Lung-only resections were performed in
14 (15 per cent) of the 95 patients, and combined resection
of lung and intra-abdominal extrahepaticmetastases on one
patient. The resection rate was higher for late than for early
metachronous disease (28⋅0 versus 17 per cent respectively;
P= 0⋅048).
The 3- and 5-year OS rates after any resection of
metachronous metastases were 78 and 62 per cent versus
42⋅1 and 18⋅2 per cent with no metastasectomy (P< 0⋅001)
(Fig. 2). Three and 5-year OS rates after any metastasec-
tomy for early metachronous metastases were 57 and 50
per cent respectively, and for late metachronous metas-
tases 84 and 66 per cent (P= 0⋅293). Three and 5-year OS
rates after liver resection for early metachronous metas-
tases were 54 and 46 per cent respectively, and for late
metachronous metastases 81 and 67 per cent (P= 0⋅319).
Fig. 2 Kaplan–Meier analysis of overall survival in 255 patients
with metachronous metastases who had resection of the pri-
mary colorectal tumour with or without metastasectomy
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Discussion
This population-based study in Finland covering the years
2000–2015 showed that the proportion of patients with
colorectal cancer diagnosed with synchronous (17⋅7 per
cent) or metachronous (19⋅6 per cent) metastases was
consistent with earlier large population-based studies7–9
reporting synchronous or metachronous metastases in
approximately 15–25 per cent of all patients with colorec-
tal cancer. Overall metastasectomy, liver and lung resection
rates for synchronous and metachronous metastases com-
pared favourably with those reported in these earlier stud-
ies. In contrast to the previous study from Sweden13, no
significant association was found between tumour sided-
ness and metastatic pattern.
Patients with synchronous metastatic disease had more
advanced primary colorectal cancers with regard to T
category and lymph node metastasis than patients without
distant metastases. In general, the node positivity rate for
colorectal cancer has consistently been some 40 per cent
across a wide range of international studies15–17. In the
present study, the node positivity rate was significantly
higher in patients with primary colorectal cancer who
developed metachronous metastases within 12months
than in patients who developed metastases 12months
or more after primary surgery. Other studies17,18 have
previously shown that high lymph node ratio is associated
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with the development of distant colorectal metastases and
reduced disease-free survival.
In comparison with previous population-based
studies7–11, a new division between synchronous and
metachronousmetastases with early and late metachronous
disease was applied in the present study, resulting in a sig-
nificant difference between these three groups regarding
resectability of metastases and survival.
The most common metastatic sites, as in ear-
lier studies7,8, were liver, lungs and intra-abdominal
extrahepatic sites. Overall, the incidence, metastatic
sites and patterns concurred with the values reported
in other studies7,8. The incidence of synchronous and
metachronous liver metastases reported here was similar
to that in other population-based series7,8,10–13. Liver-only
metastases accounted for 50⋅0 per cent of synchronous
metastases and approximately one-third of metachronous
metastases. The reported incidence of synchronous and
metachronous pulmonary metastases is 5–7⋅2 per cent7,8,
in line with the present results.
A combined metastatic pattern involving the liver was
seen frequently in the synchronous and metachronous
groups; combined liver and lung metastases were the most
frequent, followed by combined liver and extrahepatic
intra-abdominal metastases. The rate of combined liver
and lung metastases in the metachronous group was sim-
ilar to that of 5–10 per cent reported in the literature19,20,
but was almost twice as high in the synchronous group.
The presence of extrahepatic metastatic disease has long
been considered a contraindication for liver resection as
the prognosis has been poor, especially when more than
one extrahepatic site is involved. Mounting evidence cur-
rently supports resection of livermetastases and concurrent
extrahepatic metastases in well selected patients21,22. In the
present study, metastasectomy focused mainly on liver and
lung metastases and single extrahepatic sites.
Overall, the metastasectomy rate for synchronous (16⋅2
per cent) and metachronous (23⋅9 per cent) metastases
compares favourably with those of 12–23 per cent reported
in other population-based studies7. Owing to the vigilant
follow-up of patients who had surgical resection for pri-
mary colorectal cancer, the metastasectomy rate in the
present study was significantly higher in the metachronous
group than in the synchronous group. The rate of liver
resection for synchronous (18⋅3 per cent), early (29 per
cent) and late (37 per cent) metachronous liver metas-
tases is in line with a hepatectomy rate of 6⋅3–33 per cent
reported in the literature7,10,11,13,23. Pulmonarymetastasec-
tomy is generally recommended for highly selected subsets
of patients20. In the present series, lung resections were
increasingly performed using thoracoscopic approach for
synchronous (13⋅5 per cent), early (21 per cent) and late
(26 per cent) metachronous lung metastases, and the pul-
monary metastasectomy rate compares favourably with the
rate of 10 per cent reported in the literature20.
The prognosis of patients with limited lung metastases
appears to be similar to that of patients with liver metas-
tases, with a 5-year survival rate of 25–45 per cent after
resection24,25. Lung metastases presenting synchronously
with colorectal liver metastases are considered a systemic
disease, and systemic chemotherapy is the recommended
initial treatment3. However, 5- and 10-year survival rates
of 45–55 and 18 per cent respectively have been achieved
in highly selected patients who had liver and pulmonary
resection24,25.
The present results should be interpreted with some
caution, however. The number of patients is relatively
small compared with large nationwide population-based
studies. In addition, patient selection may play a significant
role in the management and outcome differences between
different studies. Different definitions have also been
used to define synchronous and metachronous metastases,
making comparison with other population-based studies
problematic. However, the population-based design makes
selection bias highly unlikely. Further strengths are reli-
able cancer recurrence data and detailed follow-up of all
patients using direct methods (medical chart review) and
the national death registry, providing a realistic picture of
the incidence and patterns of metastatic colorectal cancer,
and of the potential results of therapy at a population level
with modern staging, surgical techniques, oncological
treatments and meticulous follow-up.
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